Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Safety and Window-of-opportunity Study of Preoperative Intratumoral Injection of OX40-ligand Expressing Oncolytic Adenovirus (DNX-2440) in Patients With Resectable Liver Metastasis

NCT04714983 is registered in ClinicalTrials.gov with DNAtrix, Inc. as lead sponsor.

NCT NCT04714983
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04714983 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Safety and Window-of-opportunity Study of Preoperative Intratumoral Injection of OX40-ligand Expressing Oncolytic Adenovirus (DNX-2440) in Patients With Resectable Liver Metastasis
Lead sponsor
DNAtrix, Inc.
Phase
Phase 1
Overall status
Suspended
Start date
February 15, 2021
Completion date
December 31, 2026
Enrollment
30 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, colorectal cancer, gastric cancer, gastrointestinal stromal tumors, liver metastases, liver metastasis colon cancer, melanoma, periampullary cancer, renal cell cancer, sarcoma, squamous cell carcinoma